公司资料
Ascendis Pharma 股价、新闻与催化剂
- 股票代码:
- ASND
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Denmark
股票表现
253.29 USD (-0.60%)
收盘价
最后更新: 2026年8月21日
13.4B USD
市值
股价为何变动
As of Aug 21, 2026, ASND closed down 0.60% at $253.29. No new same-company headline was identified in the current news window.
公司概览
TransCon Technology
Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology.
Commercial Endocrinology Portfolio
YORVIPATH is a parathyroid-hormone replacement therapy for chronic hypoparathyroidism. SKYTROFA is a once-weekly growth-hormone therapy, and YUVIWEL is approved in the United States for children with achondroplasia.
Growth-Disorder Development
Ascendis is studying TransCon CNP in infants with achondroplasia and in hypochondroplasia. It is also evaluating TransCon CNP combined with TransCon hGH to address growth and skeletal complications.
Oncology Program
Onvapegleukin alfa is a long-acting IL-2 beta/gamma agonist in Phase 1/2 development, including combination treatment for platinum-resistant ovarian cancer.
未来催化剂
- European regulatory decision for YUVIWEL in the fourth quarter of 2026.
- Initiation of a Phase 3 TransCon CNP study in hypochondroplasia in the second half of 2026.
- Initiation of a Phase 3 TransCon CNP plus TransCon hGH study in pediatric achondroplasia in the fourth quarter of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。